- Dr. Reddy's sales increase by 17%
- CVS Caremark study: More education needed on genetic testing in prescribing antiplatelet drugs
- GPhA: FDA’s proposed rule on prescription drug labeling adds $4 billion to healthcare costs
- Generic drug prices spike, but PBMs' reimbursement rates don't keep up, NCPA study finds
- 21 health industry groups address FDA on proposed changes to generic drug label rules
HYDERABAD, India — Generic drug maker Dr. Reddy's Labs has launched a generic version of a drug used to prevent clotting of the blood.
Dr. Reddy's announced Friday the launch of clopidogrel tablets in the 75-mg and 300-mg strengths. The drug is a generic version of Plavix, made by Bristol-Myers Squibb and Sanofi. As one of the first companies to submit a completed regulatory application for the 300 mg strength of the drug, Dr. Reddy's received 180 days of market exclusivity for it.
Plavix had sales of $6.74 billion during the 12-month period ended in March, according to IMS Health.